Enhanced cardiovascular risk assessment from your laboratory

Introducing the PLAC® Test for Lp-PLA2 Activity (PLAC® Activity)

The PLAC® Activity Test is an FDA-cleared enzyme assay for the in vitro quantitative determination of Lp-PLA2 (lipoprotein-associated phospholipase A2) activity in ethylenediaminetetraacetic acid (EDTA) plasma and serum on automated clinical chemistry analyzers. The PLAC Activity Test is to be used in conjunction with clinical evaluation and patient risk assessment as an aid in predicting risk for coronary heart disease (CHD) in patients with no prior history of cardiovascular events.

The PLAC Activity Test is substrate based and is conveniently performed using a wide range of automated clinical chemistry analyzers.

Patients with normal cholesterol remain at risk for CHD

The PLAC Activity Test

chart 3

Flexibility and performance for the clinical laboratory

  • Validated on multiple automated chemistry analyzers
  • Robust analytical performance with high degree of accuracy and precision
  • Validated cut point of 225 nmol/min/mL

The REGARDS* multicenter study and the PLAC Activity Test

* Reasons for Geographic and Racial Differences in Stroke.

Hazard ratio bar graph

The PLAC Activity Test is analytically robust, allowing for adoption of Lp-PLA2 activity in clinical practice6


Clinical Chemistry; Vol. 59, No. 10. Supplement, 2013
Callahan H, Jaffe AS, Saenger AK; Mayo Clinic: Rochester, MN

We collaboratively developed and validated an automated Lp-PLA2 activity assay. Specific test parameters for Lp-PLA2 activity were determined using an open, user-defined channel on the Roche Cobas® 600/c501 Chemical Analyzer.

Analytical performance was established and assessed across multiple parameters:

Lp-PLA2 assay performance summary

References: 1. Sachdeva A, Cannon CP, Deedwania PC, et al. Lipid levels in patients hospitalized with coronary artery disease: an analysis of 136,905 hospitalizations in Get With The Guidelines. Am Heart J. 2009;157(1):111-117.e2. 2. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285(19):2486-2497. 3. US Preventive Services Task Force. Final recommendation statement: lipid disorders in adults (cholesterol, dyslipidemia): screening, June 2008. http://www.uspreventiveservicestaskforce.org/Page/Document/RecommendationStatementFinal/lipid-disorders-in-adults-cholesterol-dyslipidemia-screening#. Published December 2014. Accessed April 29, 2015. 4. PLAC® Test for Lp-PLA2 Activity [package insert]. South San Francisco, CA: Diadexus, Inc; 2015. 5. 3rd Annual American Society for Preventive Cardiology Cardiovascular Disease Preventive Conference, 2015. Symposium of REGARDS Lp-PLA2 Substudy. 6. Callanan H, Jaffe AS, Saenger AK. Performance evaluation of an automated assay for lipoprotein-associated phospholipase A2 (Lp-PLA2 ) activity [abstract B-316]. Clin Chem. 2013;59(S10):A1-A295.